Cullinan Therapeutics (CGEM) Free Cash Flow (2020 - 2026)

Cullinan Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$46.0 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 6.7% year-over-year to -$46.0 million in Q1 2026; TTM through Mar 2026 was -$178.7 million, a 18.93% decrease from a year earlier, with the FY2025 full-year figure at -$175.8 million, down 20.99% from the prior year.
• Free Cash Flow retreated to -$46.0 million in Q1 2026 per CGEM's latest filing, from -$38.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$18.1 million in Q4 2023 and bottomed at -$57.6 million in Q2 2025.
• The 5-year median for Free Cash Flow is -$36.6 million (2024), against an average of -$37.0 million.
• Across the five-year window, Free Cash Flow plunged 1346.07% in 2022 and soared 37.48% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$25.9 million in 2022, then rose by 29.9% to -$18.1 million in 2023, then tumbled by 102.01% to -$36.6 million in 2024, then declined by 4.08% to -$38.1 million in 2025, then retreated by 20.79% to -$46.0 million in 2026.
• Per Business Quant, the three latest CGEM Free Cash Flow figures stand at -$46.0 million (Q1 2026), -$38.1 million (Q4 2025), and -$36.9 million (Q3 2025).